Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT07748221
Starting soon Observational

Healthcare Providers' Attitudes Toward Oncology Patients With Mental Disorders

NCT07748221 · tracked via the Priya Life Science Italy tracker
Sponsor
Istituto Oncologico Veneto IRCCS
Phase
Observational
Started
2026-11-01
Last updated
2026-09-16

Condition(s) studied

Stigma of Mental IllnessCancerPsychiatric Comorbidity

Investigational drug(s) / intervention(s)

OMS-HC Questionnaire and Semi-Structured Interviews

OMS-HC Questionnaire and Semi-Structured Interviews: Participants complete an anonymous questionnaire and, where selected, participate in a semi-structured interview for research data collection purposes. No clinical or behavioural intervention is administered.

Study summary

ONCO-MinD is a multicentre, cross-sectional, non-interventional mixed-method study aimed at investigating healthcare providers' attitudes towards oncology patients with mental disorders in Italian cancer centres. The study will assess levels of mental health-related stigma among healthcare professionals and explore factors associated with these attitudes, including professional background, clinical setting, experience, and previous exposure to mental health conditions. Quantitative survey data collected using the Italian version of the Opening Minds Scale for Health Care Providers (OMS-HC) will be integrated with qualitative findings from semi-structured interviews to provide a comprehensive understanding of how stigma may influence clinical relationships, decision-making processes, and equity of cancer care.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Healthcare professionals working in participating oncology centres. * Physicians, nurses, psychologists, radiation therapy technologists, and healthcare assistants. * Direct involvement in the clinical care of oncology patients. * Employed at one of the participating study sites at the time of enrolment. * Able to understand the study information and provide informed consent. * Willing to participate in the study. For the qualitative phase, a purposive sample of participants will be selected from survey respondents who agree to be contacted for a semi-structured interview. Exclusion Criteria: * Refusal to participate or failure to provide informed consent. * Students in training. * Healthcare personnel working in services with very limited patient contact and without direct responsibility for oncology patient care.

Primary outcome measure(s)

  • Mental health-related stigma among oncology healthcare professionals — At survey completion (up to 3 months)
    Level of stigma towards people with mental disorders measured using the Italian version of the Opening Minds Scale for Health Care Providers (OMS-HC). The total score ranges from 15 to 75, with higher scores indicating greater stigma and lower scores indicating more positive attitudes towards people with mental disorders.

Trial sites (3)

FacilityCityRegionStatus
Centro Riferimento Oncologico CRO IRCCS Aviano Italy
Istituto Tumori IRCCS Giovanni Paolo II Bari Italy
The Padua, Castelfranco Veneto, and Schiavonia campuses of the Veneto Institute of Oncology (IOV-IRCCS). Padova Italy

More Istituto Oncologico Veneto IRCCS trials in Italy

First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer Active, not recruiting
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype Recruiting
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) Active, not recruiting
Regorafenib for Recurrent Meningioma (MIRAGE Trial) Recruiting
VIrtual Reality Induced Pain and anxiEty Relief in Outpatient UROlogical Procedures Recruiting

Other trials for the same condition

Study of IMC-P115C in Advanced PRAME-Positive Cancers Recruiting
Met Non Small Cell Cancer Registry (MOMENT) Recruiting
Longitudinal Registry Including Patients Treated With Heavy Particles Recruiting
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe Recruiting
Diagnostic Performance of PET/CT-PSMA in Patients With Non-prostatic PSMA-expressing Neoplasms Enrolling by invitation
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07748221 on ClinicalTrials.gov ↗ ← All trials in Italy